The Surrogate Marker for Coronary Thrombus Burden in Acute Coronary Syndrome Patients with COVID-19: The CHA2DS2-VASc Score
Öz
Aim: This study investigated whether the CHA2DS2-VASc score is an independent predictor of high thrombus burden and mortality in patients presenting with acute coronary syndrome (ACS) and Coronavirus Ddisease (COVID-19).
Materials and Methods: Patients with acute coronary syndrome (ACS) and COVID-19 (n = 76) were included in the study. They were categorized into low thrombus burden (LTB; grades 1–3) and high thrombus burden (HTB; grades 4 and 5) groups according to the final thrombus score. The CHA2DS2-VAScscores were then compared between the two groups.
Results: Post-procedural HTB developed in 50 patients (65.7%). The neutrophil-to-lymphocyte ratio (6.00 ± 3.73 vs. 11.45 ± 10.6; P < 0.05), creatinine (0.84 ± 0.22 vs. 1.51 ± 0.92 mg/dL; P < 0.05), blood urea nitrogen (42.27 ± 12.6 vs. 62.27 ± 48.2 mg/dL; P < 0.05), potassium (4.06 ± 0.35 vs. 4.51 ± 0.49 mEq/L; P < 0.05), ferritin (286 ± 55.2 vs. 730 ± 96.8 ng/mL; P < 0.05), interleukin-6 (18.12 ± 7.14 vs. 186.66 ± 56.8 pg/mL; P < 0.05), lactate dehydrogenase (425.7 ± 31.2 vs. 1002.7 ± 173.4 U/L; P < 0.05), and CHA2DS2-VASc score (2.84 ± 1.27 vs. 4.08 ± 1.61; P < 0.05) were significantly higher in the HTB group. Mortality [3 (11.5%) vs 23 (46.0%), P<0.05)] and CHA2DS2-VASc score (2.84 ± 1.27 vs 4.08 ± 1.61, P<0.05) were higher in the HTB group (Table 1).
Conclusions: In this study, the easily calculated CHA2DS2-VASc score was an independent predictor of HTB in patients with COVID-19 presenting with ACS. In addition, it predicted mortality in the same patient group.
Anahtar Kelimeler
Acute coronary syndrome, CHA2DS2-VASc score, COVID-19, high thrombus burden, low thrombus burden
Kaynakça
- 1. Ugurlucan M, Yildiz Y, Oztas DM, Coban S, Beyaz MO, Sari G, et al. Congenital cardiac interventions during the peak phase of COVID-19 pandemics in the country in a pandemics hospital in Istanbul. Cardiol Young. 2020;30(9):1288-96.
- 2. Kunal S, Gupta K, Sharma SM, Pathak V, Mittal S, Tarke C. Cardiovascular system and COVID-19: perspectives from a developing country. Monaldi Arch Chest Dis. 2020;90(2).
- 3. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pao CRR, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136(11):1330-41.
- 4. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-10.
- 5. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-segment elevation in patients with COVID-19: a case series. N Engl J Med. 2020;382(25):2478-80.
- 6. Modin D, Claggett B, Sindet-Pedersen C, Lassen MCH, Skaarup KG, Jensen JUS, et al. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020;142(21):2080-2.
- 7. Choudry FA, Hamshere SM, Rathod KS, Akhtar MM, Archbold RA, Guttmann OP, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76(10):1168-76.
- 8. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50(7):573-83.
- 9. Goto K, Lansky AJ, Nikolsky E, Fahy M, Feit F, Ohman EM, et al. Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY trial. J Am Coll Cardiol Cardiovasc Interv. 2011;4(7):769-77.
- 10. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the no-reflow phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93(2):223-8.